Pharming Shareholders appoint Karl Keegan as CFO
(Thomson Reuters ONE) -
Increase of authorized share capital
Leiden, The Netherlands, October 1, 2010. Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today the
appointment of Dr Karl Keegan as Chief Financial Officer (CFO) effective today
and the increase of its authorized share capital to 500 million shares. These
decisions were taken by the Shareholders at an Extraordinary Meeting (EGM) held
today.
The Shareholders have approved the proposal to appoint Dr Karl Keegan as CFO and
member of the Board of Management of Pharming with effect October 1, 2010. Dr
Keegan will be responsible for all financial and financing activities, corporate
communications and investor relations. In addition,Dr Keegan will work closely
together with Dr de Vries in furthering the Company's business development
activities. In addition, Pharming requested and received approval from its
Shareholders to increase the authorized number of shares from 400 million to
500 million. Prior to today's EGM, Pharming's number of outstanding shares,
available for issuance, was confined to a little over 40 million. The
possibility to, if necessary, issue additional shares, provides for sufficient
share capital to secure Pharming's financial position
Dr Sijmen de Vries, Chief Executive Officer of Pharming: "We would like to
welcome Karl to the Board of Management and look forward to working together on
the strengthening of our relationships with current and potential shareholders
and building financial stability for Pharming."
Mr Jaap Blaak, Chairman of Pharming's Board of Supervisory Directors, said:
"With the appointment of Karl as Chief Financial Officer, we consider the Board
of Management is now at optimum strength and ready to resolve the last financial
challenges. The increased authorized share capital will facilitate the Company
achieving financial stability, securing the Company's future and creating
long-term value for its Shareholders."
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic
disorders, specialty products for surgical indications, and nutritional
products. On June 24, the European Medicines Agency adopted a positive opinion
for Ruconest(TM) (Rhucin® in non-EU territories) for the treatment of angioedema
attacks. Market Authorization in the European Economic Area is therefore
expected imminently with an anticipated market launch in the fourth quarter
2010. The product is also under development for follow-on indications, i.e.
antibody-mediated rejection (AMR) and delayed graft function (DGF) following
kidney transplantation. The advanced technologies of the Company include
innovative platforms for the production of protein therapeutics, technology and
processes for the purification and formulation of these products. Additional
information is available on the Pharming website,www.pharming.com.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54
[HUG#1448383]
Press release (PDF):
http://hugin.info/132866/R/1448383/390669.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 01.10.2010 - 15:40 Uhr
Sprache: Deutsch
News-ID 43760
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 212 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming Shareholders appoint Karl Keegan as CFO"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
